|3.67||-0.0100||-0.27%||Vol 637.62K||1Y Perf 82.60%|
|May 29th, 2020 16:00 DELAYED|
|- -%||0.01 0.27%|
|Target Price||7.80||Analyst Rating||Strong Buy 1.00|
|Potential %||112.53||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-33/20||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-13/-55/12||Growth Ranking||★+ 41.14|
|Insiders Shares Cnt. % 3/6/12 mo.||19/-56/17||Income Ranking||— -|
|Market Cap||321.09M||Earnings Rating||Sell|
|Price Range Ratio 52W %||67.32||Earnings Date||7th May 2020|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.27|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||571.70K|
|Avg. Monthly Volume||797.90K|
|Avg. Quarterly Volume||794.00K|
Selecta Biosciences Inc. (NASDAQ: SELB) stock closed at 3.67 per share at the end of the most recent trading day (a -0.27% change compared to the prior day closing price) with a volume of 638.29K shares and market capitalization of 321.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 39 people. Selecta Biosciences Inc. CEO is Carsten Brunn.
The one-year performance of Selecta Biosciences Inc. stock is 82.6%, while year-to-date (YTD) performance is 54.2%. SELB stock has a five-year performance of %. Its 52-week range is between 1.28 and 4.83, which gives SELB stock a 52-week price range ratio of 67.32%
Selecta Biosciences Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 32.61, a price-to-sale (PS) ratio of 51.44, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -83.15%, a ROC of -182.90% and a ROE of -2 077.15%. The company’s profit margin is -%, its EBITDA margin is -891.30%, and its revenue ttm is $6.67 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Selecta Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Selecta Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Selecta Biosciences Inc. is Strong Buy (1), with a target price of $7.8, which is +112.53% compared to the current price. The earnings rating for Selecta Biosciences Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Selecta Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Selecta Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.29, ATR14 : 0.33, CCI20 : 74.38, Chaikin Money Flow : 0.02, MACD : 0.28, Money Flow Index : 46.31, ROC : 8.58, RSI : 61.44, STOCH (14,3) : 49.59, STOCH RSI : 0.00, UO : 44.24, Williams %R : -50.41), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Selecta Biosciences Inc. in the last 12-months were: Carsten Brunn (Option Excercise at a value of $0), Carsten Brunn (Sold 17 646 shares of value $34 821 ), Lloyd Johnston (Option Excercise at a value of $7 110), Timothy A. Springer (Buy at a value of $17 415), Timothy C. Barabe (Buy at a value of $27 200)
Copyright (c) 2020. All rights reserved. Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.com, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.